Outgoing FDA Commissioner Robert Califf, MD, has announced that Richard Pazdur, MD, who was serving as the interim director, will now be heading the Oncology Center of Excellence.
Outgoing FDA Commissioner Robert Califf, MD, has announced that Richard Pazdur, MD, who was serving as the interim director, will now be heading the Oncology Center of Excellence (OCE). The center was established in 2016 on the premise of having a coordinated clinical review of drugs, biologics, and devices across the agency’s 3 medical product centers and eliminate silos and parallel processing of what should essentially be a cohesive process.
Â
The FDA is planning a restructure within the Office of Medical Products and Tobacco so it’s be better equipped to manage the needs of cancer patients. A press release from the FDA said that while the application and review process will remain the same, “Uniting experts to collaborate on the clinical review of oncology products will enhance the agency’s work in approving safe and effective cancer products.” The OCE is also expected to improve the process of stakeholder engagement as well as advance the agency’s oncology-related regulatory and policy issues. Â
Â
As for funding, existing funds to the tune of $3.6 million will help establish OCE, according to The Cancer Letter, while the next 5 years are expected to route an additional $75 million, via the National Cancer Institute and the National Institutes of Health.
Â
Speaking with The Cancer Letter last year, Pazdur said, “I’ve always had a vision to enhance collaboration and focus our work in oncology here at the FDA in disease-specific teams. That was one of the first things I did when I became the director of what was then the Division of Oncology Products in CDER [Center for Drug Evaluation and Research], and I think the OCE is a continuation of that across medical products.”
Â
Cancer organizations are reacting warmly to the news. Clifford Hudis, MD, CEO of the American Society of Clinical Oncology, expects the OCE to create a bigger community of scientists and clinical experts within the FDA. “ASCO looks forward to working with the OCE and the new administration to help improve the lives of people living with cancer,” Hudis said.
The American Association for Cancer Research (AACR) also congratulated Pazdur on his appointment. “The AACR looks forward to working with Pazdur and his staff in the months and years to come, as they have worked for years to build collaborative partnerships with academia, industry, other government agencies, scientific societies, and patient advocacy organizations to improve both the pace and the quality of new cancer drugs reaching patients,” said AACR president Nancy Davidson, MD.
What We’re Reading: RSV Vaccine Demand; Permanent Contraception; Drug Negotiation Impact
December 8th 2023The Biden administration recently met with manufacturers of respiratory syncytial virus (RSV) immunizations to encourage them to increase access to the vaccine; since the Dobbs v Jackson decision, many patients have been seeking more permanent reproductive health care solutions; a Mathematica analysis showed that Medicare prescription drug price negotiations could have cut seniors’ out-of-pocket costs by nearly a quarter had the program been in effect in 2021.
Read More
Patients With HFrEF, HFpEF See Different Functional Capacity Benefits With Dapagliflozin
December 7th 2023The DETERMINE-Reduced and DETERMINE-Preserved trials demonstrated varying benefits of dapagliflozin on Kansas City Cardiomyopathy Questionnaire Total Symptom Score and Physical Limitation Scale as well as 6-minute walk distance.
Read More
Black Patients With Ulcerative Colitis Less Likely to Undergo IPAA Than White Patients
December 7th 2023Overall, the number of patients discharged from hospitals with an ulcerative colitis diagnosis increased between 2009 and 2018, but the number of patients opting for ileal pouch–anal anastomosis (IPAA) decreased.
Read More
Prediction Model Identified Risk Factors for ED Visits in Patients With Lung Cancer
December 7th 2023A risk prediction model that was based on machine learning could help to make resource utilization more efficient by correctly predicting emergency department (ED) visits in patients with lung cancer.
Read More